Editas Medicine Inc（EDIT）價格預測EDITEditas Medicine Inc

Alphio's EDIT stock price prediction model matches the current Editas Medicine Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.39 (-0.51%). The 1-week path is $2.43 (+1.45%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Editas Medicine Inc is a good buy right now due to its recent approval for the Phase 1/2 clinical trial of EDIT-401, which has shown promising results in reducing bad cholesterol levels by approximately 90%. The current price of $2.40 is significantly below the analyst price target of $6, indicating a potential upside of 150%. Additionally, the company's gross margin remains strong at 100%, showcasing its ability to maintain profitability despite current losses. The main risk is the company's negative net income, which was -$18.23 million in Q2 2026, indicating ongoing financial challenges that investors should monitor.

Editas Medicine Inc (EDIT) last closed at $2.4, losing -3.61%. These facts feed the 1-day and 1-week EDIT price prediction above.